Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03702309 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Study acronym: LIBERATE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 6, 2026 → Jul 6, 2027
See other at-risk trials from University Health Network, Toronto

Record History

  1. Primary and study completion pushed from Jul 6, 2026 to Jul 6, 2027 Secondary endpoints: details revised at 1 of 2 entries · Publications: details revised at 5 of 5 entries · Eligibility criteria expanded, about 4 words Show 3 more changesShow less
    • Secondary endpoints: details revised at 1 of 2 entries
    • Publications: details revised at 5 of 5 entries
    • Eligibility criteria expanded, about 4 words
  2. Primary and study completion dates: Jul 6, 2025 to Jul 6, 2026v11
  3. Primary and study completion dates: Jul 6, 2024 to Jul 6, 2025v10
  4. Re-verified, no change to tracked fieldsv9
  5. Primary and study completion dates: Jul 2023 to Jul 6, 2024v8
Show 6 earlier versionsHide 6 earlier versions
  1. Trial status: Active, Not Recruiting to Recruiting Site details revisedv7 Show 1 more changeShow less
    • Site details revised
  2. Primary and study completion dates: Jul 2022 to Jul 2023 Trial status: Recruiting to Active, Not Recruiting · Site details revisedv6 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
  3. 2 versions Re-verified since Sep 24, 2019, no change to tracked fieldsv4-v5
  4. Site contact updatedv3
  5. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University Health Network, Toronto
433 trials monitored
See 27 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 7 more diseases
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.
Trial Details
NCT Number NCT03702309
Lead Sponsor University Health Network, Toronto
Conditions Cancer, Breast Cancer, Lung Cancer, Colon Cancer, Ovarian Cancer, Melanoma, Lymphoma, Leukemia +10 more
Enrollment 2,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov